About alirocumab
PCSK9 inhibitor monoclonal antibody
Used for
- Lowers LDL cholesterol in adults with familial or other primary hypercholesterolemia.
- Reduces cardiovascular risk in adults with established cardiovascular disease.
Usual adult dose
Usually 75 mg under the skin every 2 weeks, or 300 mg every 4 weeks. Increase to 150 mg every 2 weeks if needed.
Usual dose in children
For inherited heterozygous familial hypercholesterolemia, ages 8 years and older: usually 75 mg every 4 weeks; adjust according to LDL response.
Common side effects
- Injection-site reactions
- Common cold-like symptoms
- Itching
- Allergic reactions
Important warnings
- Serious allergic reactions, including angioedema, can occur.
- Monitor LDL cholesterol and adjust treatment as needed.
- Use alongside diet and other cholesterol-lowering treatment when prescribed.
Pregnancy
Human pregnancy data are limited; use only when the expected benefit outweighs potential risk.
Breastfeeding
It is unknown whether alirocumab passes into breast milk; consider benefits and potential risks.
Interactions
- No important drug interactions are established.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.